Below, you will find a selection of recent publications by all principal investigators involved in the CRU 344. For a more extensive overview of their scientific work, please refer to the PI’s website or their respective reference list linked below.

A list of all publications submitted by members of this CRU can be found here.

Univ.-Prof. Dr. med. Rafael Kramann (P1)

Kramann R, Schneider RK. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Blood. 2018

Kramann R, Machado F, Wu H, et al. Parabiosis and single-cell RNA sequencing reveal a limited contribution of monocytes to myofibroblasts in kidney fibrosis. JCI Insight. 2018

See full reference list on PubMed.

Prof. Dr. rer. nat. Gerhard Müller-Newen (P2)

Kuepper MK, Bütow M, Herrmann O, Müller-Newen G, et al. Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling. Leukemia. 2019

Martincuks A, Andryka K, Küster A, Schmitz-Van de Leur H, Komorowski M, Müller-Newen G. Nuclear translocation of STAT3 and NF-κB are independent of each other but NF-κB supports expression and activation of STAT3. Cell Signal. 2017

See full reference list on PubMed.

Dr. rer. nat. Mirle Schemionek-Reinders (P2)

Bilich T, Nelde A, Bichmann L, Schemionek M, et al. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood. 2019

Kirschner M, Maurer A, Wlodarski MW, Schemionek M, et al. Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia. 2018

See full reference list on PubMed.

Univ.-Prof. Dr. med. Rebekka Schneider (P3)

Schneider RK, Mullally A, Dugourd A, et al. Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target. Cell Stem Cell. 2018

El Agha E, Kramann R, Schneider RK, et al. Mesenchymal Stem Cells in Fibrotic Disease. Cell Stem Cell. 2017

See full reference list on PubMed.

Dr. rer. nat. Nicolas Chatain (P4)

Baumeister J, Chatain N, Hubrich A, et al. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Leukemia. 2020

Maifrede S, Nieborowska-Skorska M, Chatain N, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018

See full reference list on PubMed.

Univ.-Prof. Dr. rer. nat. Martin Zenke (P4)

Li Z, Schulz MH, Look T, Begemann M, Zenke M, Costa IG. Identification of transcription factor binding sites using ATAC-seq. Genome Biol. 2019

Sontag S, Förster M, Zenke M, et al. Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells. Stem Cells. 2017

See full reference list on PubMed.

Univ.-Prof. Dr. med. Tim H. Brümmendorf (P5)

Röllig C, Kramer M, Brümmendorf TH, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? [published online ahead of print, 2020 Jun 4]. Blood. 2020

Eipel M, Božić T, Brümmendorf TH, et al. Tracking myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides. Haematologica. 2019

See full reference list on PubMed.

Univ.-Prof. Dr. med. Dr. rer. nat. Wolfgang Wagner (P5)

Brown A, Schuetz D, Wagner W, et al. The lifespan quantitative trait locus gene Securin controls hematopoietic progenitor cell function. Haematologica. 2020

Zirkel A, Nikolic M, Wolfgang W, et al. HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF Clustering across Cell Types. Mol Cell. 2018

See full reference list on PubMed.

Univ.-Prof. Dr. med. Steffen Koschmieder (P6)

Rao TN, Hansen N, Koschmieder S, et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood. 2019

Czech J, Cordua S, ..., Koschmieder S. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2019

See full reference list on PubMed.

Univ.-Prof. Dr. rer. nat. Ivan Costa (SP1)

Frank S, Ahuja G, Costa IG, et al. yylncT Defines a Class of Divergently Transcribed lncRNAs and Safeguards the T-mediated Mesodermal Commitment of Human PSCs. Cell Stem Cell. 2019

Nascimento ACA, Prudêncio RBC, Costa IG. A Drug-Target Network-Based Supervised Machine Learning Repurposing Method Allowing the Use of Multiple Heterogeneous Information Sources. Methods Mol Biol. 2019

See full reference list on PubMed.